MedTrace Logo

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

NCT05314738 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-07-08

No results posted yet for this study

Summary

Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.

Conditions

  • Progressive Keratoconus

Interventions

COMBINATION_PRODUCT

NXL Energy 1

Riboflavin drops + NXL System to Total Energy Level 1

COMBINATION_PRODUCT

NXL Energy 2

Riboflavin drops + NXL System to Total Energy Level 2

COMBINATION_PRODUCT

NXL Energy 3

Riboflavin drops + NXL System to Total Energy Level 3

COMBINATION_PRODUCT

Sham Treatment

Sham Drops and No exposure to NXL system

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-08
Primary Completion
2025-08-31
Completion
2026-02-28
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05314738 on ClinicalTrials.gov